Catequentinib
Genital Diseases, Female
Wenjun ChengSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Genital Diseases, Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Udayana University | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Udayana University | Phase 4 | BB |
Carboplatin Wenjun Cheng | Phase 3 | BB |
Metformin M.D. Anderson Cancer Center | Phase 3 | BB |
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
View all 12 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →